Clinical nuclear medicineHumansMaleProstatic NeoplasmsCastration-ResistantMiddle Aged
The Effectiveness of Low-dose 161 Tb-PSMA Treatment for Metastatic Castration-resistant Prostate Cancer.
Fucen Liu, Xia Yang, Liming Xiao, Zhaohui Zhu, Zhengguo Chen
Published: 202610.1097/RLU.0000000000006241
Abstract
A 60-year-old man with metastatic castration-resistant prostate cancer (mCRPC), previously treated with antiandrogen therapy, experienced continued PSA rise and disease progression. He subsequently received 2 cycles of low-dose 161 Tb-PSMA radioligan…
Preview only. Read the full abstract at the source